Pavmed INC

PAVmed Inc. stockholders re-elected two directors and approved amendments to the Employee Stock Purchase Plan at the 2026 Annual Meeting.

PAVmed Inc. announced its first quarter 2026 financial results and provided a business update, highlighting progress in its subsidiaries Veris Health and Lucid Diagnostics, alongside advancements in its relaunched medical device portfolio.

PAVmed reported Q4/FY2025 results, strengthened its balance sheet with $45M in new financing, eliminated convertible overhang, and advanced Veris and Lucid programs toward key regulatory and reimbursement milestones.

PAVmed Inc. stockholders approved proposals for stock issuance, director removal, and an increase in the equity incentive plan shares at a special meeting.

PAVmed Inc. announced the closing of $30 million in Series D Convertible Preferred Stock and a $15 million senior secured note, eliminating all previously outstanding convertible securities and strengthening its balance sheet.

PAVmed Inc. announced it has regained compliance with Nasdaq's $1 minimum bid price requirement, avoiding potential delisting.

PAVmed reports Q1 2026 financial results, highlighting a $30 million Series D financing, debt restructuring, and continued commercialization efforts for its subsidiaries.

PAVmed Inc. reported a net loss for Q3 2025, facing a going concern warning while advancing subsidiary products and addressing Nasdaq compliance through a proposed reverse stock split.

PAVmed reports reduced operating losses and increased cash, driven by strategic restructuring and subsidiary financings, despite ongoing going concern doubts and Nasdaq compliance issues.

PAVmed Inc. reports a net income attributable to common stockholders of $17.7 million for Q1 2025, driven by fair value adjustments in equity method investments, while navigating liquidity challenges and strategic shifts.

PAVmed Inc. reported its third quarter 2024 results, marked by a significant gain from the deconsolidation of Lucid Diagnostics, but also ongoing operational losses and financial uncertainties.

PAVmed Inc. reported a net loss of $10.9 million for the second quarter of 2024, with revenue of $1.0 million, primarily driven by EsoGuard testing.

PAVmed Inc. reports significant financial restructuring, including a reverse stock split and capital raises, while advancing its medical device and diagnostics portfolio amidst ongoing operating losses.

PAVmed Inc. details its financial performance for 2024, highlights strategic initiatives including Lucid Diagnostics' deconsolidation, and addresses Nasdaq compliance while focusing on Veris Health and its incubator program.

PAVmed Inc.'s 10-K filing outlines its capital structure, including common stock, warrants, preferred stock, and convertible notes, as well as anti-takeover provisions.

Victoria Tou-ho Lee, Chief Medical Officer of PAVmed Inc., was granted 70,000 shares of restricted stock.

PAVM Director Lishan Aklog reported the acquisition of 350,000 restricted shares under the company's Long-Term Incentive Equity Plan.

PAVM Inc. reports that President and CFO Dennis M. McGrath was granted 180,000 shares of restricted stock under the company's Long-Term Incentive Equity Plan.

PAVmed Inc. director Michael J. Glennon acquired 13,930 shares of common stock through a restricted stock grant.

PAVmed Inc. reports that Director Timothy Baxter acquired 13,930 shares of common stock on April 2, 2026, as part of a restricted stock grant.

PAVmed Inc. reports that Director Debra White acquired 13,930 shares of common stock as restricted stock under an equity incentive plan.

PAVmed Inc. has issued its 2026 proxy statement detailing proposals for director elections, an ESPP amendment, and auditor ratification.

PAVmed Inc. calls a special meeting to approve significant equity issuances, a corporate governance amendment, and an increase in its equity incentive plan, following a $30 million private placement and debt refinancing.

PAVmed Inc. will hold a special meeting on December 5, 2025, to seek stockholder approval for a reverse stock split and a reduction in authorized common stock to regain Nasdaq compliance and attract institutional investors.

PAVmed Inc. supplements its proxy statement to include the full text of the amended 2014 Long-Term Incentive Equity Plan for the upcoming annual meeting.

Pavmed Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

PAVmed Inc. is soliciting proxies for its annual meeting on June 18, 2025, to vote on key proposals including director elections, stock issuance approval, an equity plan amendment, executive compensation, and auditor ratification.

Lishan Aklog, Chairman and CEO of PAVmed Inc., reports beneficial ownership of 5.1% of the company's common stock.

PAVmed Inc. filed an Amendment No. 6 to its Schedule 13D, detailing an updated beneficial ownership of 27.5% in Lucid Diagnostics Inc. and new agreements impacting voting control.

PAVmed Inc. has increased its beneficial ownership in Lucid Diagnostics Inc. to 28.3%, solidifying its influence through new stock awards and voting agreements.

Two Seas Capital LP and affiliates have reported a 9.99% beneficial ownership stake in PAVmed Inc. common stock.

First Manhattan Co. LLC, FMC Group Holdings LP, and First Manhattan Management LLC collectively report beneficial ownership of 9.6% of PAVmed Inc.'s common stock as of March 31, 2026.

Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri have filed a Schedule 13G reporting a 9.99% beneficial ownership stake in PAVmed Inc.

Tasso Partners, LLC and Dana Carrera report combined beneficial ownership of 15.3% of PAVmed Inc. common stock as of March 27, 2026.

Scopia Holdings LLC and Matthew Sirovich report beneficial ownership of 9.9% of PAVmed Inc. common stock, totaling 637,670 shares.

David S. Nagelberg and the David S. Nagelberg 2003 Revocable Trust have jointly filed a Schedule 13G, disclosing beneficial ownership of 8.6% of PAVmed Inc.'s common stock.